This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
28 Aug 2013

Porvair Launches Genuine 2 mL Deep Well Plate

Porvair Sciences has developed the first 96-well round deep well plate that genuinely delivers 2.00 mL liquid capacity/well in an automation compatible SLAS/ANSI footprint. The revolutionary "common wall" design provides a full 2 mL round well, round bottom well within a 45-mm height limit, thus ensuring full compatibility with most plate handling equipment.

Unlike other '2 mL' deep well plates that typically offer just 1.80–1.90 mL well, the new Porvair plate enables labs involved with fraction collecting, compound storage, plate replication and mixing applications the chance to use the full 2.00 mL well capacity without compromise.

Manufactured under class 10,000 conditions from ultra-pure grade polypropylene, Porvair's new 2.00 mL 96-well deep well plates are certified as RNase/DNase free and contain no measurable contaminants that could otherwise leach out and affect the sample. For sterile biological applications, Porvair 2.00 mL 96-well deep well plates are available irradiated. A matching thermoplastic elastomer "cap mat" provides easy friction sealing of this new plate for transport, shipping and short-term storage. For longer periods, the new 2.00 mL plate can be heat sealed using Porvair Sciences aluminium or clear heat seals together with the company's Miniseal II thermal sealer to provide a range of peelable, peirceable and re-sealable storage options.

Measuring just 45 mm high, Porvair 2.00 mL 96-well deep well plates are compatible with microplate stackers, washers and automated equipment. The new plate design incorporates features that prevent 'locking' when stacked and enable easy heat sealing.

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.